Modelling olanzapine-induced weight gain in rats

International Journal of Neuropsychopharmacology

Volumn 17, Issue 1, 2014, Pages 169-186

  Van Der Zwaal, E M ^a   Janhunen, S K ^b   La Fleur, S E ^a   Adan, R A H ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ORION CORPORATION   (Finland)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antipsychotic; energy balance; olanzapine; rat models; weight gain

Indexed keywords

AGOUTI RELATED PROTEIN; AMINO ACID; CHOLECYSTOKININ; ESTROGEN; FATTY ACID; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HISTAMINE H1 RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LEPTIN; OLANZAPINE; PEPTIDE YY; TESTOSTERONE; BENZODIAZEPINE DERIVATIVE;

ANOREXIA; BASAL METABOLIC RATE; BODY COMPOSITION; BODY FAT; BODY TEMPERATURE; BODY WEIGHT; BRAIN METABOLISM; COGNITION; DOSE RESPONSE; DRUG HALF LIFE; EMOTION; ENERGY BALANCE; ENVIRONMENTAL FACTOR; EXERCISE; EXPERIMENTAL MODEL; FAT INTAKE; FEEDING BEHAVIOR; FOOD INTAKE; FOOD PREFERENCE; GENETIC VARIABILITY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; LIPID STORAGE; LOCOMOTION; MEAL; MOTIVATION; NONHUMAN; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RAT; RAT STRAIN; RESTING ENERGY EXPENDITURE; REVIEW; REWARD; SATIETY; SEDENTARY LIFESTYLE; STOMACH DISTENSION; THERMOGENESIS; WEIGHT GAIN; ANIMAL; BIOLOGICAL MODEL; CALORIC INTAKE; DISEASE MODEL; DRUG EFFECTS; ENERGY METABOLISM; PREDICTIVE VALUE;

ANIMALS; BENZODIAZEPINES; DISEASE MODELS, ANIMAL; ENERGY INTAKE; ENERGY METABOLISM; HUMANS; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; RATS; WEIGHT GAIN;

EID: 84888604282     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114571300093X     Document Type: Review

References (123)

1. Ahnaou A, Megens AA, Drinkenburg WH (2003) The atypical antipsychotics risperidone, clozapine and olanzapine differ regarding their sedative potency in rats. Neuropsychobiol 48:47-54. (Pubitemid 36928715)
2. Albaugh VL, Henry CR, Bello NT, Hajnal A, Lynch SL, Halle B, Lynch CJ (2006) Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring) 14:36-51. (Pubitemid 46214773)
3. Albaugh VL, Judson JG, She P, Lang CH, Maresca KP, Joyal JL, Lynch CJ (2011) Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol Psychiatry.
4. Allan GF, Tannenbaum P, Sbriscia T, Linton O, Lai MT, Haynes-Johnson D, Bhattacharjee S, Zhang X, Sui Z, Lundeen SG (2007) A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behaviour in female rats. Endocrine 32:41-51. (Pubitemid 350242546)
5. Aravagiri M, Teper Y, Marder SR (1999) Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20:369-377. (Pubitemid 30449775)
6. Arjona AA, Zhang SX, Adamson B, Wurtman RJ (2004) An animal model of antipsychotic-induced weight gain. Behav Brain Res 152:121-127. (Pubitemid 38597070)
7. Bamshad M, Song CK, Bartness TJ (1999) CNS origins of the sympathetic nervous system outflow to brown adipose tissue. Am J Physiol 276:R1569-R1578. (Pubitemid 29323518)
8. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD (2001) Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 62:231-238. (Pubitemid 32428761)
9. Belanoff JK, Blasey CM, Clark RD, Roe RL (2011) Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats. Eur J Pharmacol 655:117-120.
10. Berridge KC (1996) Food reward: brain substrates of wanting and liking. Neurosci Biobehav Rev 20:1-25. (Pubitemid 126682107)
11. Berthoud HR (2002) Multiple neural systems controlling food intake and body weight. Neurosci Biobehav Rev 26:393-428.
12. Biswasl PN, Wilton LV, Pearcel GL, Freemantle S, Shakir SA (2001) The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol 15:265-271. (Pubitemid 34024244)
13. Blass DM, Chuen M (2004) Olanzapine-associated hypothermia. Psychosomatics 45:135-139. (Pubitemid 38270719)
14. Blouin M, Tremblay A, Jalbert ME, Venables H, Bouchard RH, Roy MA, Almeras N (2008) Adiposity and eating behaviours in patients under second generation antipsychotics. Obesity (Silver Spring) 16:1780-1787.
15. Blundell JE, Halford JC (1994) Regulation of nutrient supply: the brain and appetite control. Proc Nutr Soc 53:407-418.
16. Bromel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg JC, Hebebrand J (1998) Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 3:76-80. (Pubitemid 28045189)
17. Brown S, Birtwistle J, Roe L, Thompson C (1999) The unhealthy lifestyle of people with schizophrenia. Psychol Med 29:697-701. (Pubitemid 29261358)
18. Bushe C, Shaw M, Peveler RC (2008) A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 22:46-55.
19. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol 14:87-96. (Pubitemid 26053226)
20. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM (1999) Olanzapine-Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37:177-193.
21. Chintoh AF, Mann SW, Lam TK, Giacca A, Remington G (2008) Insulin resistance following continuous, chronic olanzapine treatment: an animal model. Schizophr Res 104:23-30.
22. Choi S, DiSilvio B, Unangst J, Fernstrom JD (2007) Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sci 81:1024-1030. (Pubitemid 47384786)
23. Cilia J, Piper DC, Upton N, Hagan JJ (2001) Clozapine enhances breakpoint in common marmosets responding on a progressive ratio schedule. Psychopharmacol (Berl) 155:135-143. (Pubitemid 32417821)
24. Clegg DJ, Brown LM, Woods SC, Benoit SC (2006) Gonadal hormones determine sensitivity to central leptin and insulin. Diabetes 55:978-987. (Pubitemid 44100172)
25. Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ (2005) A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacol (Berl) 181:80-89. (Pubitemid 41440918)
26. Cooper GD, Pickavance LC, Wilding JP, Harrold JA, Halford JC, Goudie AJ (2007) Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol 21:405-413. (Pubitemid 47077303)
27. Cooper GD, Goudie AJ, Halford JC (2010) Acute effects of olanzapine on behavioural expression including the behavioural satiety sequence in female rats. J Psychopharmacol 24:1069-1078.
28. Costa e Silva JA, Alvarez N, Mazzotti G, Gattaz WF, Ospina J, Larach V, Starkstein S, Oliva D, Cousins L, Tohen M, Taylor CC, Wang J, Tran PV (2001) Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. J Clin Psychopharmacol 21:375-381. (Pubitemid 32673026)
29. D'Alessio DA, Kavle EC, Mozzoli MA, Smalley KJ, Polansky M, Kendrick ZV, Owen LR, Bushman MC, Boden G, Owen OE (1988) Thermic effect of food in lean and obese men. J Clin Invest 81:1781-1789.
30. Dallman MF (2010) Stress-induced obesity and the emotional nervous system. Trends Endocrinol Metab 21:159-165.
31. Davoodi N, Kalinichev M, Clifton PG (2008) Comparative effects of olanzapine and ziprasidone on hypophagia induced by enhanced histamine neurotransmission in the rat. Behav Pharmacol 19:121-128. (Pubitemid 351365689)
32. Davoodi N, Kalinichev M, Korneev SA, Clifton PG (2009) Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. Psychopharmacol (Berl) 203:693-702.
33. Donahoo WT, Levine JA, Melanson EL (2004) Variability in energy expenditure and its components 1. Curr Opin Clin Nutr Metab Care 7:599-605. (Pubitemid 40340629)
34. Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M, Kemmler G, Lechleitner M, Fleischhacker WW (2001) Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 158:1719-1722. (Pubitemid 32923669)
35. Evers SS, Calcagnoli F, van Dijk G, Scheurink AJ (2010) Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats. Pharmacol Biochem Behav 97:163-169.
36. Fell MJ, Marshall KM, Williams J, Neill JC (2004) Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J Psychopharmacol 18:149-155. (Pubitemid 38954901)
37. Fell MJ, Neill JC, Rao C, Marshall KM (2005a) Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats. Psychopharmacol 182:499-507. (Pubitemid 41464631)
38. Fell MJ, Gibson R, McDermott E, Sisodia G, Marshall KM, Neill JC (2005b) Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats. Behav Brain Res 160:338-343. (Pubitemid 40603530)
39. Fell MJ, Anjum N, Dickinson K, Marshall KM, Peltola LM, Vickers S, Cheetham S, Neill JC (2007) The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacol (Berl) 194:221-231. (Pubitemid 47457949)
40. Fell MJ, Neill JC, Anjum N, Peltola LM, Marshall KM (2008) Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats. J Psychopharmacol 22:182-186. (Pubitemid 351322855)
41. Ferno J, Varela L, Skrede S, Vazquez MJ, Nogueiras R, Dieguez C, Vidal-Puig A, Steen VM, Lopez M (2011) Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLoS ONE 6: e20571. doi:10.1371/journal.pone. 0020571.
42. Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, Most MM, Fryburg DA (2010) Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring) 18:1646-1651.
43. Fukunishi I, Sato Y, Kino K, Shirai T, Kitaoka T (2003) Hypothermia in a hemodialysis patient treated with olanzapine monotherapy. J Clin Psychopharmacol 23:314. (Pubitemid 36807798)
44. Gao K, Ganocy SJ, Gajwani P, Muzina DJ, Kemp DE, Calabrese JR (2008) A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 69:302-309. (Pubitemid 351469274)
45. Gebhardt S, Theisen FM, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg JC, Kuhnau W, Schmidtke J, Remschmidt H, Hebebrand J (2010) Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. J Clin Pharm Ther 35:207-211.
46. Gerardo-Gettens T, Moore BJ, Stern JS, Horwitz BA (1989) Prolactin stimulates food intake in a dose-dependent manner. Am J Physiol 256:R276-R280.
47. Ghibaudi L, Cook J, Farley C, van HM, Hwa JJ (2002) Fat intake affects adiposity, comorbidity factors, and energy metabolism of Sprague-Dawley rats. Obes Res 10:956-963. (Pubitemid 135688910)
48. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, Poraz I, Frishman S, Constantini N, Zalsman G, Weizman A, Apter A (2002) Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 159:1055-1057. (Pubitemid 34586957)
49. Goudie AJ, Smith JA, Halford JC (2002) Characterization of olanzapine-induced weight gain in rats. J Psychopharmacol 16:291-296. (Pubitemid 35470572)
50. Goudie AJ, Cole JC, Sumnall HR (2007) Olanzapine withdrawal/ discontinuation-induced hyperthermia in rats. Prog Neuropsychopharmacol Biol Psychiatry 31:1500-1503. (Pubitemid 47304479)
51. Graham KA, Perkins DO, Edwards LJ, Barrier RC Jr., Lieberman JA, Harp JB (2005) Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 162:118-123. (Pubitemid 40095680)
52. Guesdon B, Denis RG, Richard D (2010) Additive effects of olanzapine and melanin-concentrating hormone agonism on energy balance. Behav Brain Res 207:14-20.
53. Han M, Deng C, Burne TH, Newell KA, Huang XF (2008) Short-and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinol 33:569-580.
54. Hartfield AW, Moore NA, Clifton PG (2003) Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacol 167:115-122. (Pubitemid 36628151)
55. Heil SH (1999) Sex-specific effects of prolactin on food intake by rats. Horm Behav 35:47-54. (Pubitemid 29100808)
56. Henderson DC, Borba CP, Daley TB, Boxill R, Nguyen DD, Culhane MA, Louie P, Cather C, Eden EA, Freudenreich O, Taber SM, Goff DC (2006) Dietary intake profile of patients with schizophrenia. Ann Clin Psychiatry 18:99-105. (Pubitemid 43879897)
57. Hillebrand JJ, van Elburg AA, Kas MJ, van Engeland H, Adan RA (2005) Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa? Biol Psychiatry 58:651-657. (Pubitemid 41565580)
58. Horton TJ, Drougas H, Brachey A, Reed GW, Peters JC, Hill JO (1995) Fat and carbohydrate overfeeding in humans: different effects on energy storage. Am J Clin Nutr 62:19-29.
59. Huang XF, Han M, Huang X, Zavitsanou K, Deng C (2006) Olanzapine differentially affects 5-HT2Aand2C receptor mRNA expression in the rat brain. Behav Brain Res 171:355-362. (Pubitemid 43946500)
60. Jolley S, Garety PA, Ellett L, Kuipers E, Freeman D, Bebbington PE, Fowler DG, Dunn G (2006) A validation of a new measure of activity in psychosis. Schizophr Res 85:288-295. (Pubitemid 43947529)
61. Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, Ignar DM, Jones DN (2005) Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacol (Berl) 182:220-231. (Pubitemid 41464615)
62. Kalinichev M, Rourke C, Jones DNC (2006) Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone vs. olanzapine. Behav Pharmacol 17:289-292.
63. Kapur S, Vanderspek SC, Brownlee BA, Nobrega JN (2003) Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625-631. (Pubitemid 36459179)
64. Kent S, Hurd M, Satinoff E (1991) Phentolamine and thermoregulation in rats. Pharmacol Biochem Behav 40:709-716.
65. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH (2007) From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 104:3456-3459. (Pubitemid 46364180)
66. Kirk SL, Neill JC, Jones DN, Reynolds GP (2004) Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. Eur J Pharmacol 505:253-254. (Pubitemid 39535699)
67. Kirk SL, Glazebrook J, Grayson B, Neill JC, Reynolds GP (2009) Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacol (Berl) 207:119-125.
68. Kluge M, Schuld A, Himmerich H, Dalal M, Schacht A, Wehmeier PM, Hinze-Selch D, Kraus T, Dittmann RW, Pollmacher T (2007) Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol 27:662-666. (Pubitemid 351339453)
69. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S (2010) Olanzapine vs. other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (3):CD006654.
70. Lambert M, Holzbach R, Moritz S, Postel N, Krausz M, Naber D (2003) Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. Int Clin Psychopharmacol 18:251-260. (Pubitemid 37041409)
71. Lechan RM, Fekete C (2006) The TRH neuron: a hypothalamic integrator of energy metabolism. Prog Brain Res 153:209-235. (Pubitemid 44107417)
72. Lee MD, Clifton PG (2002) Meal patterns of free feeding rats treated with clozapine, olanzapine, or haloperidol. Pharmacol Biochem Behav 71:147-154. (Pubitemid 34102473)
73. Leshner AI, Siegel HI, Collier G (1972) Dietary self-selection by pregnant and lactating rats. Physiol Behav 8:151-154.
74. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo LC, Schwarz S, Davis JM (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152-163.
75. Levine JA (2002) Non-exercise activity thermogenesis (NEAT). Best Pract Res Clin Endocrinol Metab 16:679-702.
76. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223. (Pubitemid 41345943)
77. Liebig M, Gossel M, Pratt J, Black M, Haschke G, Elvert R, Juretschke HP, Neumann-Haefelin C, Kramer W, Herling AW (2010) Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. Obesity (Silver Spring) 18:1952-1958.
78. Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T, Knudsen LB (2008) The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr Res 103:94-103.
79. Martins PJ, Haas M, Obici S (2010) Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes 59:2418-2425.
80. Mathews J, Newcomer JW, Mathews JR, Fales CL, Pierce KJ, Akers BK, Marcu I, Barch DM (2012) Neural correlates of weight gain with olanzapine. Arch Gen Psychiatry 69:1226-1237.
81. McCreadie RG (2003) Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 183:534-539. (Pubitemid 37533200)
82. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD (2007) Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164:1050-1060. (Pubitemid 47121394)
83. Meil WM, Schechter MD (1997) Olanzapine attenuates the reinforcing effects of cocaine. Eur J Pharmacol 340:17-26. (Pubitemid 28033971)
84. Minet-Ringuet J, Even PC, Guesdon B, Tome D, de Beaurepaire R (2005) Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection. Behav Brain Res 163:204-211. (Pubitemid 41138054)
85. Minet-Ringuet J, Even PC, Lacroix M, Tome D, de Beaurepaire R (2006a) A model for antipsychotic-induced obesity in the male rat. Psychopharmacol 187:447-454. (Pubitemid 44200516)
86. Minet-Ringuet J, Even PC, Goubern M, Tome D, de Beaurepaire R (2006b) Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite 46:254-262. (Pubitemid 43867820)
87. Morrison SF, Nakamura K, Madden CJ (2008) Central control of thermogenesis in mammals. Exp Physiol 93:773-797. (Pubitemid 351904256)
88. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW (2006) Central nervous system control of food intake and body weight. Nature 443:289-295. (Pubitemid 44435142)
89. Muller AP, Tort AH, Gnoatto J, Moreira JD, Vinade ER, Perry ML, Souza DO, Lara DR, Portela LV (2010) Metabolic and behavioural effects of chronic olanzapine treatment and cafeteria diet in rats. Behav Pharmacol 21:668-675.
90. Newcomer JW (2007) Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68(Suppl. 1):20-27.
91. Novak CM, Levine JA (2007) Central neural and endocrine mechanisms of non-exercise activity thermogenesis and their potential impact on obesity. J Neuroendocrinol 19:923-940. (Pubitemid 350131079)
92. Parsons B, Allison DB, Loebel A, Williams K, Giller E, Romano S, Siu C (2009) Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 110:103-110.
93. Pouzet B, Mow T, Kreilgaard M, Velschow S (2003) Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 75:133-140. (Pubitemid 36577588)
94. Raskind MA, Burke BL, Crites NJ, Tapp AM, Rasmussen DD (2007) Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacol 32:284-288. (Pubitemid 46106935)
95. Ravussin E, Lillioja S, Anderson TE, Christin L, Bogardus C (1986) Determinants of 24-hour energy expenditure in man. Methods and results using a respiratory chamber. J Clin Invest 78:1568-1578. (Pubitemid 17219520)
96. Rising R, Harper IT, Fontvielle AM, Ferraro RT, Spraul M, Ravussin E (1994) Determinants of total daily energy expenditure: variability in physical activity. Am J Clin Nutr 59:800-804. (Pubitemid 24112515)
97. Roerig JL, Mitchell JE, de Zwaan M, Crosby RD, Gosnell BA, Steffen KJ, Wonderlich SA (2005) A comparison of the effects of olanzapine and risperidone vs. placebo on eating behaviours. J Clin Psychopharmacol 25:413-418. (Pubitemid 41368362)
98. Roth BL, Sheffler DJ, Kroeze WK (2004) Magic shotguns vs. magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359. (Pubitemid 38499762)
99. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123:225-233.
100. Scherk H, Pajonk FG, Leucht S (2007) Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 64:442-455. (Pubitemid 46556468)
101. Schwartz MW, Woods SC, Porte D Jr., Seeley RJ, Baskin DG (2000) Central nervous system control of food intake. Nature 404:661-671. (Pubitemid 30205071)
102. Sejima E, Yamauchi A, Nishioku T, Koga M, Nakagama K, Dohgu S, Futagami K, Kataoka Y (2011) A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats. Cell Mol Neurobiol 31:985-989.
103. Shobo M, Yamada H, Mihara T, Kondo Y, Irie M, Harada K, Ni K, Matsuoka N, Kayama Y (2011a) Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone. Behav Brain Res 216:561-568.
104. Shobo M, Yamada H, Koakutsu A, Hamada N, Fujii M, Harada K, Ni K, Matsuoka N (2011b) Chronic treatment with olanzapine via a novel infusion pump induces adiposity in male rats. Life Sci 88:761-765.
105. Silva JE (2006) Thermogenic mechanisms and their hormonal regulation. Physiol Rev 86:435-464.
106. Skrede S, Ferno J, Vazquez MJ, Fjaer S, Pavlin T, Lunder N, Vidal-Puig A, Dieguez C, Berge RK, Lopez M, Steen VM (2012) Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol 15:163-179.
107. Smith GC, Vickers MH, Shepherd PR (2011) Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. Arch Physiol Biochem 117:241-249.
108. Snigdha S, Thumbi C, Reynolds GP, Neill JC (2008) Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. J Psychopharmacol 22:567-571.
109. Stefanidis A, Verty AN, Allen AM, Owens NC, Cowley MA, Oldfield BJ (2009) The role of thermogenesis in antipsychotic drug-induced weight gain. Obesity (Silver Spring) 17:16-24.
110. Strassnig M, Brar JS, Ganguli R (2003) Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull 29:393-397. (Pubitemid 37187700)
111. Theisen FM, Linden A, Konig IR, Martin M, Remschmidt H, Hebebrand J (2003) Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm 110:111-121. (Pubitemid 36135558)
112. Thornton-Jones Z, Neill JC, Reynolds GP (2002) The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study. J. Psychopharmacol 16:35-37. (Pubitemid 34273071)
113. Treuer T, Hoffmann VP, Chen AK, Irimia V, Ocampo M, Wang G, Singh P, Holt S (2009) Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study. World J Biol Psychiatry 10:729-740.
114. van der Zwaal EM, Luijendijk MC, Adan RA, la Fleur SE (2008) Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution. Eur J Pharmacol 585:130-136.
115. van der Zwaal EM, Luijendijk MC, Evers SS, la Fleur SE, Adan RA (2010) Olanzapine affects locomotor activity and meal size in male rats. Pharmacol Biochem Behav 97:130-137.
116. van der Zwaal EM, Janhunen SK, Luijendijk MC, Baclesanu R, Vanderschuren LJ, Adan RA, la Fleur SE (2012a) Olanzapine and sibutramine have opposing effects on the motivation for palatable food. Behav Pharmacol 23:198-204.
117. van der Zwaal EM, Merkestein M, Lam YK, Brans MA, Luijendijk MC, Bok LI, Verheij ER, la Fleur SE, Adan RA (2012b) The acute effects of olanzapine on ghrelin secretion, CCK sensitivity, meal size, locomotor activity and body temperature. Int J Obes (Lond) 36:254-261.
118. Victoriano M, Hermier D, Even PC, Fromentin G, Huneau JF, Tome D, de Beaurepaire R (2009) Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats. Psychopharmacol (Berl) 206:167-176.
119. Vidarsdottir S, Vlug P, Roelfsema F, Frolich M, Pijl H (2010) Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study. J Clin Psychiatry 71:1205-1211.
120. Wallingford NM, Sinnayah P, Bymaster FP, Gadde KM, Krishnan RK, McKinney AA, Landbloom RP, Tollefson GD, Cowley MA (2008) Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. Neuropsychopharmacol 33:2922-2933.
121. Wang L, Saint-Pierre DH, Tache Y (2002) Peripheral ghrelin selectively increases Fos expression in neuropeptide Y-synthesizing neurons in mouse hypothalamic arcuate nucleus. Neurosci Lett 325:47-51. (Pubitemid 34521976)
122. Weston-Green K, Huang XF, Deng C (2011) Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behav Brain Res 217:337-346.
123. Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, Strakowski SM, Sharma T, Kahn RS, Gur RE, Tollefson GD, Lieberman JA (2005) Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 187:537-543.